| Name | Title | Contact Details |
|---|
Cyberonics, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
ZipLine® Medical is developing and commercializing innovative tissue repair devices to address the clinical need for rapid, non-invasive and easy-to-use skin closure. ZipLine`s PRELOC™ technology platform provides uniform closure forces while minimizing scar-promoting tension along the wound. Utilizing our patented technology, we believe that physicians can achieve the best of both worlds — the speed of staples with the cosmetic outcome of a meticulous suture closure. Our initial strategy focuses on procedures where the non-invasive, speed and cosmetic benefits of our technology have the greatest impact. Since skin closure is a part of most surgical procedures, our technology platform has broad application across various surgical specialties and emergency medicine. ZipLine Medical was founded in 2009 by Amir Belson, M.D. and is located in Silicon Valley, with access to a wealth of expertise in medical device research and development
Biotricity is a medical technology company committed to improving healthcare by developing solutions that aid chronic disease prevention and management. Biotricity`s premier product is Bioflux, an ECG monitoring system that will be prescribed by physicians to diagnose and remotely monitor cardiac patients.
ActiveCare, Inc. provides patented diabetes and chronic disease management and wellness solutions that increase visibility, lower costs and provide real-time care for members resulting in improved outcomes. Utilizing state-of-the-art meters with embedded cellular technology, trained CareSpecialists can intervene in real-time and provide members with the support needed to control their disease 24 hours a day, every day. ActiveCare's solution is revolutionizing the way employers, individuals and their health plans monitor chronic disease.
Elucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid equips physicians with critical information designed to enable precision medicine. Elucid is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA transcripts (“Virtual Transcriptomics”). This unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs. The Elucid software is available for commercial use in the U.S. and Europe